Board of Directors
Noubar Afeyan, Ph.D. Chairman of the Board Noubar Afeyan, Ph.D., is one of BG Medicine’s co-founders and has served on the board of directors since the company’s inception in 2000. He is also a Senior Lecturer at MIT’s Sloan School of Management and has authored numerous scientific publications and patents since earning his Ph.D. in Biochemical Engineering from MIT in 1987. A technologist, entrepreneur and venture capitalist, Dr. Afeyan has co-founded and helped build over 20 successful life science and technology startups during the past two decades. He was founder and CEO of PerSeptive Biosystems (Nasdaq: PBIO), a leader in the bio-instrumentation field. After PerSeptive's acquisition by Applera Corporation (NYSE: ABI), he was Senior Vice President and Chief Business Officer of Applera, where he initiated and oversaw the creation of Celera Genomics (Nasdaq: CRA). Currently Dr. Afeyan serves on a number of public and private company boards. He is a director and co-founder of Flagship portfolio companies Affinnova, BG Medicine, Ensemble Discovery, Helicos BioSciences (NASDAQ:HLCS), Joule Biotechnologies and LS9. Previously he was a member of the founding team, director and investor in several successful ventures including Chemgenics Pharmaceuticals, Color Kinetics, Antigenics, EXACT Sciences and Adnexus Therapeutics. Dr. Afeyan is a member of several advisory boards including the Deshpande Center for Technological Innovation at MIT, the Whitehead Institute at MIT, the Harvard-MIT Division of Health Sciences and Technology (HST), the SKOLKOVO School of Management in Moscow and the Board of Overseers of Boston University. He is also a member of the Board of Overseers of the Boston Symphony Orchestra. Dr. Afeyan is co-founder and board member of Armenia 2020 and the National Competitiveness Foundation of Armenia, two international economic development projects focusing on the former Soviet Republic of Armenia. back to top Harrison M. Bains Director Harrison M. Bains joined BG Medicine’s board of directors in June 2007. Mr. Bains served as Vice President and Treasurer of Bristol Myers Squibb Company from 1988 until his retirement in 2004. Mr. Bains career also includes serving as Senior Vice President of the Primary Industries Group at Chase Manhattan Bank and 11 years with RJR Nabisco and two of its predecessor companies as Senior Vice President and Treasurer. He currently serves as the chair of the board of directors and the chair of the audit committee of MGI Funds, Inc. He is a member of the boards of trustees of the University of Redlands, the Greater Newark Conservancy, the Park Avenue Armory, the Civil War Preservation Trust and Summer Search. Mr. Bains earned an M.B.A. from the University of California, Berkeley and a B.A. in economics from the University of Redlands. He also completed the Advanced Management Program at Harvard Business School. back to top Stéphane Bancel Director Stéphane Bancel has served on BG Medicine’s board of directors since January 2010. Mr. Bancel has served as Chief Executive Officer of bioMérieux, a world leader in the field of in vitro diagnostics for clinical and industrial applications since January 2007, and prior to that, served as Vice President of Strategy. Prior to his tenure at bioMérieux, Mr. Bancel worked for Eli Lilly Laboratories in the United States, Great Britain and Belgium, where he successively held the positions of Managing Director, Executive Director for Global Manufacturing Strategy, Global Supply Chain and U.S. Distribution, and Supply Chain Manager. From 1995 to 1998, Mr. Bancel worked with bioMérieux in Japan, where he managed the industrial microbiology business for the Asia-Pacific region. During the past five years, Mr. Bancel has served on the board of directors of Targanta Therapeutics Corp. and he currently serves on the board of directors of bioTheranostics and Knome. Mr. Bancel is a graduate of the Ecole Centrale Paris Engineering School. He holds an M.S. in biochemical engineering from the University of Minnesota and an M.B.A. from Harvard Business School. back to top Timothy Harris, Ph.D. Director Timothy Harris, Ph.D., joined BG Medicine’s board of directors in April 2007. Dr. Harris currently serves as the Director of the Advanced Technology Program at SAIC Frederick and Chief Technology Officer for SAIC Frederick. Prior to holding these positions, he served as the President & Chief Executive Officer of Novasite Pharmaceuticals Inc., and as President and Chief Executive Officer for Structural GenomiX, Inc. (now part of Eli Lilly). Dr. Harris started his career in biotechnology as a group leader in Molecular Biology at Celltech Group (now UBC Pharma) and acted as Director of Biotechnology at Glaxo Group Research in the UK. Dr. Harris also held the Chief Scientific Officer and Vice President of Research and Development position at Sequana Therapeutics Inc. in San Diego, which became Axys Pharmaceuticals, Inc., and was subsequently acquired by Celera Genomics. Dr. Harris has served on the board of directors of Dendreon Corp. and he currently serves on the boards of directors of Novation Pharmaceuticals, Inc. and Origen Therapeutics, Inc. and is Chairman of the Scientific Advisory Board of Bionomics Inc. in Australia. Dr. Harris received his Ph.D. in molecular virology from the University of Birmingham, U.K. back to top Pieter Muntendam, M.D. Director, President and CEO Pieter Muntendam, M.D., is President and CEO of BG Medicine since November 2004. He is a biopharmaceutical and healthcare executive with in-depth business experience ranging from early stage ventures to multinational corporations. Dr. Muntendam joined BG Medicine from NetNumina Solutions, Inc., a professional services company, where he served as Director of the Biopharma Healthcare Practice. Prior to joining NetNumina, he co-founded Vitivity Inc., a subsidiary of Millennium Pharmaceuticals, Inc., and served as Vice President, Medicine. Dr. Muntendam founded the health management firm ProMedex Inc. in 1996, where he served as President & Chief Executive Officer and chairman of the board until ProMedex was acquired by Landacorp, Inc. Prior to that, he served as Vice President of Care Management at Glaxo Wellcome (now GlaxoSmithKline). Dr. Muntendam held executive positions with Organon International Inc. and Johnson&Johnson where he was appointed Vice President of Research and Development, International at Johnson & Johnson, and appointed as a member of the boards of directors for two Johnson & Johnson operating companies. Dr. Muntendam received his M.D. from Leiden University in the Netherlands. back to top Stelios Papadopoulos, Ph.D. Vice Chairman of the Board Stelios Papadopoulos, Ph.D., has served on BG Medicine’s board of directors since 2003 and as Vice Chairman of the board of directors since April 2007. Since 2000, he has served as Chairman of Fondation Sante, a private charitable foundation whose mission is to improve the health and education of those in need, whether countries, regions or individuals. Dr. Papadopoulos served as Vice Chairman of Cowen and Company, LLC and as Managing Director. While at Cowen and Company, LLC, he worked as an investment banker focused on the biotech and pharmaceutical sectors. Prior to joining Cowen and Company, LLC, he worked as an investment banker at PaineWebber, Incorporated, where he was Chairman of PaineWebber Development Corp., a PaineWebber subsidiary focusing on biotechnology. Dr. Papadopoulos is a co-founder and Chairman of the Board of Exelixis, Inc., and he is a co-founder and member of the boards of directors of Anadys Pharmaceuticals, Inc. and Cellzome, Inc. Dr. Papadopoulos also serves on the board of directors of Biogen Idec, Inc., Regulus Therapeutics, Inc. and Joule Biotechnologies, Inc. He is also a member of the board of visitors of Duke University School of Medicine and the board of directors of the National Marrow Donor Program. Dr. Papadopoulos holds a Ph.D. in biophysics and an M.B.A. in finance, both from New York University. back to top Pieter van der Meer, M.Sc. Director Pieter van der Meer, M.Sc., has served on BG Medicine’s board of directors since February 2002. Since January 2005, he has served as a Managing Director of Gilde Healthcare Partners, a venture capital firm, where he focuses on start-up and early stage investments in healthcare companies with novel technologies, platforms and drug discovery approaches. Mr. van der Meer also represents Gilde on the boards of directors of certain of its portfolio companies, including Agendia B.V., Ablynx N.V. and Acacia Pharma Ltd. He is also a member of the project screening committee at Amsterdam & Leiden Universities. Mr. van der Meer joined Gilde after working several years with KPMG Management Consulting, where he was closely involved with due diligence and strategic projects in venture capital and the pharmaceutical sector across Europe. Mr. van der Meer earned his M.Sc. in chemistry at Leiden University where he specialized in bio-organic synthesis and molecular modeling. back to top |